Personalizing anti-rejection medicines after a heart transplant
Part of Heart & circulation, Immune system & allergy clinical trials.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received a heart transplant less than 2 weeks ago.
- You are 18 years or older.
- You are on a standard anti-rejection plan with prednisolone, tacrolimus, and mycophenolate.
- If you could become pregnant, you must use effective birth control during the study and for 3 months after.
- You cannot have had a multi-organ transplant (like heart and kidney).
- You cannot be pregnant or planning pregnancy during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
This study looks at using two anti-rejection medicines (everolimus and a lower dose of a calcineurin inhibitor) after a heart transplant. The goal is to see if this combination is safe and effective for keeping your body from rejecting the new heart, while possibly protecting your kidneys compared to standard treatment.
This trial is studying whether a blood test that measures small molecules called microRNAs can help doctors personalize the medicines used to prevent rejection after a heart transplant. If you qualify, you would help researchers learn how to better match immunosuppression to each patient's needs.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
This study is looking at heart transplant children (up to age 18) to see if measuring tiny molecules called microRNAs in the blood can help doctors personalize anti-rejection medicines. It aims to improve how we prevent rejection while reducing side effects.
Hear when a new Heart Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.